Coordinated national tendering and combined policies were linked to the highest biosimilar uptake in 8 countries. Anti-TNF uptake topped 70% in Denmark, Germany, and Italy vs ~40% in Australia. Read more here: hubs.li/Q04BNG3q0 🌍 #GlobalBiosimilarsWeek #Policyshapesaccess

FDA’s draft PK guidance could cut biosimilar PK study costs by up to 50%, per Commissioner Makary. Teva’s Robert Cook, PhD, says analytical characterization plus PK data will guide its next program. 🔬 Watch here: hubs.li/Q04BMh4g0 #GlobalBiosimilarsWeek

In a 462-patient Italian study, switching from reference ustekinumab to a #biosimilar held up in Crohn disease: 92.2% clinical success vs 92.7% on the originator at 6 months, evidence that supports #access to lower-cost #biologics. hubs.li/Q04BCTPw0 #GlobalBiosimilarsWeek

Biosimilars saved US health care $25.4B in 2025. This #GlobalBiosimilarsWeek, our October newsletter covers Teva’s Degevma approval, FDA’s leaner PK guidance, and new switching data, all pointing to lower costs and broader access to biologics. 🌍 hubs.li/Q04zXx2L0

🗳️ Looking ahead to Global Biosimilars Week: which biosimilars topic tops your list—access, #affordability, #biologics costs, or #healthinnovation? Vote in The Center for Biosimilars’ LinkedIn poll: hubs.li/Q04Bh-3n0

Bipartisan bills would automatically delay Medicare negotiation selection for biologics facing biosimilar competition. Meanwhile, California expands biosimilar substitution. Read more: hubs.li/Q04z_W920 #Biosimilars #Access #Affordability

🔬 Following Teva’s denosumab approval, Robert Cook, PhD, discussed biosimilars, pricing, and reliable supply—market considerations shaping #access, #affordability, and #biologics costs. Read our interview: hubs.li/Q04z_Y3h0 #HealthInnovation

Biosimilars saved US health care $25.4B in 2025, up about 26% from 2024, and $81.6B since 2015, per AAM. Real savings, but uptake still trails its potential. Affordability depends on access. 💰 #GlobalBiosimilarsWeek hubs.li/Q04zXz770

💡 Biosimilars saved US health care $25.4B in 2025, and FDA’s push to streamline PK testing could reshape how these biologics are developed. Our October newsletter breaks down what it means for #access, #affordability, #costs, and #healthinnovation. 🔗 hubs.li/Q04zP3TV0

Teva's Degevma, a denosumab biosimilar to Xgeva, is FDA-approved, completing its Xgeva/Prolia pair, as 10 companies now hold both. As competition grows, whether lower costs expand access to these #biologics is up to payers. 🦴 hubs.li/Q04z8cds0 #Biosimilars

📊 Biosimilars and generics are reshaping the cost conversation in US health care. As savings reach $496B, the market signal is clear: broader #access, #affordability, and smarter #biologics competition matter for patients and the system. Read more here: hubs.li/Q04ykn5b0

🔍 New AAM/IQVIA data shows generics and biosimilars drove $496B in 2025 savings. What do these findings signal for health innovation, biologics competition, #access, #affordability, and long-term costs? Keep an 👁️ out for our analysis here: hubs.li/Q04xZjJ70

New study: Most pediatric IBD patients maintain stable disease after switching from adalimumab originator to biosimilar. Insights may support access, affordability, and improved biologic care. #IBD #Biosimilars #Pediatrics Read more here: hubs.li/Q04xMcDD0

Analytical characterization builds trust in monoclonal antibody biosimilars, showing strong similarity to reference biologics and supporting broader access and reduced costs. hubs.li/Q04xBz3M0 #Biosimilars #Healthcare #Pharma

📊 New data on infliximab biosimilar switching in IBD suggest remission and trough levels were maintained after the switch, adding to the evidence on #biosimilars, #access, #affordability, #biologics, and #healthinnovation in care delivery. Read more here: hubs.li/Q04xv9770

💬 What do you want to see more of in the next issue of #TheBiosimilarsBulletin? We’re polling our audience on the topics shaping #biosimilars, #biologics, #access, and #affordability. Vote on our LinkedIn poll: hubs.li/Q04x7HSM0'

🔬ICYMI: Our latest #BiosimilarsBulletin covers biosimilar competition, affordability, payer dynamics, and new real-world evidence across key biologics. Catch up here: hubs.li/Q04x7yl70 #Biosimilars #Access

🧬 Real-world IBD research found that switching from originator infliximab to biosimilar CT-P13 preserved remission over 2 years, with comparable drug clearance. Biosimilars can support #healthinnovation, #access, #affordability, and #biologics costs. hubs.li/Q04w-kXM0

🔬 New IRIS Registry study: Sequential anti-VEGF step therapy may raise costs and delay care, highlighting key issues in biosimilars and access. Explore the findings: hubs.li/Q04wKqVH0 #HealthPolicy #Biosimilars

ICYMI: The latest #Biosimilars Bulletin explores how competition can expand access to biologic therapies—and what policy and market changes could mean for affordability. Read more here: hubs.ly/Q04wKp4T0